Introduction
Mitochondria provide the majority of the ATP required for normal neuronal function. In accordance with this energetic role, a chronic decrease in mitochondrial ATP-generating capacity resulting either from genetic alterations to components of the mitochondrial respiratory chain or ATP synthase, or from dysfunction of any of these complexes, is implicated in the pathogenesis of aging and neurodegenerative disorders. Additionally, acute disruption of mitochondrial bioenergetics resulting from Ca 2ϩ overload and/or generation of reactive oxygen species plays a major contributory role in the cell death associated with brain ischaemia.
In addition to their principal function of ATP production, it has been discovered that mitochondria participate directly in the induction of programmed cell death (apoptosis) by releasing pro-apoptotic proteins. This pro-active role for mitochondria in a cell death pathway may link the competence of mitochondria to produce ATP with the decision to enter the apoptotic pathway. The present article will attempt to outline the significance of mitochondrial dysfunction in a number of neuronal disease states.
Bioenergetic functions of brain mitochondria
Neurons, in common with most cell types, expend energy to combat the constant inward leak of Na ϩ and Ca 2ϩ . However, along with other excitable cells, neurons additionally need to restore their ion gradients following controlled fluxes of ions across the cell membrane during electrical signalling. The task of maintaining the ionic homoeostasis in neurons falls largely to ATP-consuming plasma membrane ion pumps such as the Na ϩ , K ϩ -ATPase and the Ca 2ϩ -ATPase. In fact, most of the ATP consumed by these cells is utilized by these pumps and is generated by mitochondria.
The mitochondrial proton circuit provides the link between the energyyielding transfer of electrons from NADH or FADH 2 to the final electron acceptor (O 2 ) and the energy-requiring synthesis of ATP ( Figure 1) . Three of the respiratory chain complexes (I, III and IV) translocate protons from the matrix across the mitochondrial inner membrane into the inter-membrane 44 Essays in Biochemistry volume 33 1998
Figure 1. Mitochondrial respiratory chain inhibitors mimic neurodegenerative disorders
The mitochondrial respiratory chain consists of five multisubunit protein complexes (complexes I-V, also known as NADH-UQ oxidoreductase, succinate dehydrogenase, UQ-cytochrome c oxidoreductase, cytochrome c oxidase and ATP synthase respectively) plus two mobile electron carriers, ubiquinone (Q) and cytochrome c (cyt c). The electron transport chain (complexes I-IV, ubiquinone and cytochrome c) carry reducing equivalents from NADH and FADH 2 in sequence from ubiquinone to complex III, cytochrome c, complex IV and finally to oxygen, which is reduced to water. The extrusion of protons (H ϩ ) by complexes I, III and IV is coupled to the movement of electrons, generating a proton electrochemical gradient. Protons re-enter the matrix through the ATP synthase to generate ATP. Numerous toxins are known to interfere specifically with mitochondrial respiratory chain function: 1-methyl-4-phenylpyridinium (MPP ϩ ) and 3-nitropropionic acid (3-NPA) have led to primate models of Parkinson's disease and Huntington's disease respectively. Inhibition of complex III is not currently associated with any known neurological condition, although it is inhibited by the pro-apoptotic substance, ceramide. Among the large number of mitochondrial genetic disorders are Leber's Hereditory Optic Neuropathy (LHON), which affects a subunit of complex I, and neuropathy, ataxia and retinitis pigmentosa (NARP), which affects a subunit of the ATP synthase. For a comprehensive review, see [26] . space, generating an electrochemical gradient of protons. This is referred to as the proton motive force (⌬p), and consists of two components: ⌬pH, the concentration difference of protons across the membrane, and ⌬, the membrane potential [1] . The proton circuit is completed by the ATP synthase (also known as complex V), which couples the re-entry of protons through the inner membrane to the synthesis of ATP from ADP and P i . The ⌬ component is also utilized to accumulate Ca 2ϩ from the cytoplasm whenever its concentration rises above a 'set-point' of about 0.3Ϫ0. Mitochondrial ATP synthesis is a complex and fragile process which is vulnerable to a large number of factors. In addition to direct inhibition by acute substrate or oxygen deprivation, more chronic effects can be caused by Ca 2ϩ overload or cumulative oxidative damage, which may increase the permeability of the inner membrane to protons and/or inhibit mitochondrial metabolism [3] . Current research is focused on two interrelated principles: that cells may die if their capacity for ATP synthesis falls below their peak ATP demand, and that damaged mitochondria may trigger the programmed destruction of the cell.
Mitochondria and excitotoxicity
Many studies show that in acute neurological injuries, such as ischaemia or head trauma, glutamate is released during the insult and the ensuing neuronal death is associated with pathological, excitotoxic activation of N-methyl-D-aspartate (NMDA) receptors [4] . Failure of mitochondrial ATP synthesis in ischaemic neurons leads to a decline in plasma membrane Na ϩ and K ϩ gradients and a massive efflux of glutamate, mostly of cytoplasmic origin [5] . The combination of high extracellular glutamate and lowering of the neuronal plasma membrane potential, which will alleviate the potential-dependent Mg 2ϩ block of the NMDA receptor ion channel, leads to a prolonged activation of the receptor and consequent Ca 2ϩ entry across the postsynaptic membrane. This will proceed after re-oxygenation until the plasma membrane is repolarized and glutamate is re-accumulated by the cells. There is overwhelming evidence that this Ca 2ϩ entry is responsible for the initiation of the neuron's death [4] . During this process the mitochondria accumulate large amounts of Ca 2ϩ . Under certain conditions, isolated mitochondria respond to massive Ca 2ϩ loading with the production of reactive oxygen species and a catastrophic permeabilization of their inner membrane, the 'mitochondrial permeability transition' [3] . It has been proposed that this latter event may trigger both programmed (apoptotic) and necrotic neuronal cell death [6] . Thus inhibitors which prevent mitochondria from accumulating Ca 2ϩ protect cells in vitro against glutamate excitotoxicity [7] .
The role of these mechanisms in the much slower, selective neuronal cell death characteristic of neurodegenerative disorders is more speculative. However, in general, relatively mild defects in neuronal metabolism may pre-dispose neurons to NMDA-receptor-mediated excitotoxicity in response to otherwise sublethal concentrations of glutamate [8] .
Mitochondrial hypotheses for neurodegenerative disorders
Disorders in oxidative phosphorylation caused by mutations in mitochondrial DNA (mtDNA) or the effects of mitochondrial inhibitors (see Figure 1 ) suggest that disturbances in mitochondrial oxidative phosphorylation may play a role in a variety of degenerative processes, such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD) and amyotrophic lateral sclerosis. Indeed, a gradual electron transport 'run-down' may be associated with normal aging. mtDNA accumulates mutations faster than does chromosomal DNA, and this is presumed to be due to oxygen radical-induced damage during the lifetime of an individual. Thus accumulation of mtDNA mutations in post-mitotic senescent tissues may result in bioenergetic deficiency [9] . As discussed above, the mitochondria themselves are an important source of damaging oxygen radicals and are protected from them by various antioxidant systems. Neurodegenerative disorders are characterized by a slow onset and often progressive loss of certain populations of neurons. Neurons are particularly sensitive to inhibition of oxidative phosphorylation, and this can be demonstrated by the ability of mitochondrial toxins to induce neuronal cell death [8] . Impairment of particular sites within the respiratory chain is thought to underlie the differences in the neurodegenerative disorders (Figure 1 ), although all points of inhibition would be expected to result in a decreased capacity for production of ATP. A sensitization to glutamate excitotoxicity may underlie many of the neurodegenerative consequences of these mitochondrial lesions [8] .
Parkinson's disease PD is a common, late-onset disease associated with movement disorders and loss of dopaminergic neurons in the substantia nigra. Several factors are implicated in the pathogenesis of PD; these include increased deposition of iron in the substantia nigra, enhanced oxidative stress due to monoamine oxidase activity and respiratory chain inhibition, genetic predisposition, and weak excitotoxicity as a consequence of defects in oxidative phosphorylation [10] . While each of these can be demonstrated to play a part in the selective destruction of dopaminergic neurons in PD, and are not necessarily mutually exclusive, the weak excitotoxicity theory, which depends upon a chronic decrease in ATP, currently receives the most attention [10] . Mitochondrial defects have been studied extensively in tissues from PD patients and recently also in cybrid cells [cells in which the native mtDNA has been destroyed, usually by ethidium bromide treatment, and the cells repopulated with the mutant mitochondria from the patient, usually from platelets (since these cells lack nuclear DNA)]. Thus mtDNA from a PD patient inserted into a neuroblastoma cell line resulted in decreased complex I activity [11] . However, other studies have not observed detectable changes in complex I proteins in PD.
Inhibition of complex I with either rotenone or 1-methyl-4-phenylpyridinium (MPP ϩ ) [the metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)] has been shown to cause the selective loss of dopaminergic neurons when injected in vivo [12] . Furthermore, the development of severe PDlike symptoms by intravenous drug users was associated with contamination of the narcotics by MPTP. It was subsequently demonstrated that MPTP is oxidized to MPP ϩ by monoamine oxidase B, found in both glial cells and serotonergic neurons in the brain, and then actively transported into nigrostriatal dopaminergic neurons by the dopaminergic uptake system. Once inside these neurons, MPP ϩ is then accumulated within the mitochondrial matrix in response to ⌬, where it exerts its inhibitory effect on complex I.
In addition to these studies with poisoned mitochondria, deficiencies in oxidative phosphorylation have been found in the platelets, muscle and brain of PD patients. A decrease in complex I activity of 26% was found in the cybrids formed from the combination of PD platelet mtDNA and a neuroblastoma cell line depleted of mtDNA [11] . The PD cybrids were also found to be less effective at restoring the basal cytoplasmic free Ca 2ϩ concentration following a Ca 2ϩ load. However, bypassing complex I by donating electrons into the respiratory chain at complex II using succinate (Figure 1 ) could partially restore PD cybrid Ca 2ϩ recovery [11] . The fact that PD patient platelet and muscle mitochondria demonstrate a deficit in complex I activity would seem to indicate the presence of a mtDNA lesion rather than the specific accumulation of an environmental toxin by the affected neurons. However, this is an oversimplification, and the symptoms of PD appear to be biochemically and genetically heterogeneous, indicating both genetic and environmental inhibition of oxidative phosphorylation.
The inhibition of complex I per se appears to be accompanied by the generation of reactive oxygen species such as superoxide [13] , which may additionally cause oxidative damage to the other respiratory chain complexes. Interestingly, inhibition of complex III (by antimycin A, but not by myxothiazol) greatly enhances superoxide generation [13] , although inhibition of complex III is currently not associated with any known neurological condition. This implies that oxidative damage in PD may be secondary to the respiratory chain deficiency.
Alzheimer's disease AD is the most common neurodegenerative disease of later life and manifests clinically as a progressive cognitive decline. The primary mechanisms initiating neuronal degeneration in AD are not yet resolved, although several potential pathogenic mechanisms are known. While the primary focus of research has been on the involvement of tau hyperphosphorylation, amyloid ␤ peptide and the amyloid precursor protein [14] , there is evidence implicating impaired metabolic function and oxidative stress in AD, with a focus on deficits in complex IV activity (Figure 1 ). Thus complex IV activity post mortem has been reported to be reduced by 25Ϫ30% in the frontal, temporal, parietal and occipital cortex of AD brains [15] . In addition, AD cybrids formed from patient platelet mtDNA and a mtDNA-depleted neuroblastoma cell line demonstrated a 52% decrease in complex IV activity compared with control cybrids [16] . However, not all studies have shown mitochondrial defects in AD brain biopsies, and a recent claim that mutations in two of the complex IV genes encoded by mtDNA (CO1 and CO2) were demonstrated to be inherited in a maternal fashion, and to segregate at a higher frequency with AD [17] , has been reported to be artifactual [18] . The significance of a complex IV deficiency as a causative factor in AD is thus still controversial.
Huntington's disease HD is associated with the selective loss of neurons in the basal ganglia. The nuclear gene defect responsible for HD results in an abnormal polyglutamine extension of a protein, huntingtin, of unknown function. While huntingtin is not located in mitochondria, several lines of evidence implicate the involvement of an energetic defect and consequent oxidative damage in HD. Inhibition of complex II by systemic administration of 3-nitropropionic acid in rats and primates (Figure 1 ) is used to produce animal models displaying lesions that closely resemble the neuropathological features of HD [19] . The lesion induced by systemic or intrastriatal injection of 3-nitropropionic acid is associated with metabolic impairment and, interestingly, is also age-dependent, in that young animals are more resistant to its neurotoxic effects [19] .
Mitochondrial encephalopathies, neuropathies and myopathies
The mitochondrion has between two and ten molecules of mtDNA, which encodes 13 polypeptides and all the machinery required for their transcription and translation. Importantly, mtDNA lacks a protective histone coat and the normal repair enzymes associated with nuclear DNA. Thus mtDNA acquires mutations at a much higher rate than nuclear DNA [9] . The 13 polypeptides encoded by mtDNA are all subunits of the respiratory chain complexes; they include six subunits of complex I, cytochrome b, the three larger subunits of complex IV, and one subunit of the ATP synthase. The remaining mitochondrial proteins (90Ϫ95% of the total) are encoded by nuclear DNA and are imported post-translationally via specific translocation systems. Clearly, defects in mitochondria-or nuclear-encoded enzymes, or in their transport or assembly, could lead to dysfunction of the respiratory chain. Tissues with high rates of aerobic metabolism, such as brain, retina, and cardiac and skeletal muscle, are particularly vulnerable to decreases in oxidative phosphorylation.
The disorders presented by mutations in mtDNA are particularly interesting from a genetic point of view, firstly because mtDNA is inherited in a maternal fashion, and secondly because there are thousands of copies of mtDNA in each cell, so that the phenotypic expression of a mitochondrial gene will depend on the relative proportions of mutant and wild-type mtDNAs within a cell. The latter, in conjunction with mitochondria replicating in post-mitotic cells, results in heteroplasmy of any mitochondrial mutation within cells.
To date, a number of deleterious mtDNA mutations have been identified, including both maternally inherited point mutations and sporadic large-scale rearrangements. Patients may present at any age with symptoms ranging from acute episodes of lactic acidosis in infancy to severe neurodegenerative illness in adulthood. Unfortunately, while advances in molecular genetics techniques have facilitated the diagnosis and characterization of specific molecular defects, there is a lack of definitive biochemical therapies. In most cases, the phenotypic expression of the mtDNA mutation varies depending on the degree of mitochondrial heteroplasmy within different tissues of the same individual (segregative replication).
Mitochondria and programmed cell death
A chronic decrease in ATP and overstimulation of excitatory receptors may be associated with the above neurodegenerative disorders, but how the neurons die following this is not entirely clear. It is known that apoptosis (programmed cell death) is an ATP-requiring pathway, and that if cellular ATP levels fall too low during a death-inducing stimulation then necrosis (disordered cell death) ensues [20] . Mitochondrial dysfunction is actively involved in the initiation of apoptosis, and mitochondria additionally participate in the signalling pathway that culminates in nuclear chromatin condensation. An initiating signal for apoptosis appears to be incipient damage in a critical proportion of the cell's mitochondria, signalled by their release of pro-apoptotic factors, rather than a subsequent collapse in ATP. Indeed, if neurons or human T-cells [20] are depleted of ATP, apoptosis is no longer possible, and necrosis ensues.
The protein Bcl-2 is a potent inhibitor of apoptosis induced by various signals, and is mainly localized to the mitochondrial outer membrane. The mechanism by which Bcl-2 functions is still controversial. Antioxidant or pore formation have been proposed, although the clearest phenotype observed with mitochondria isolated from a neural cell line overexpressing Bcl-2 is a decreased susceptibility to the permeability transition [21] .
Mitochondrial swelling as a consequence of the permeability transition ruptures the outer membrane and allows release of pro-apoptotic factors from the intermembrane space. To date, two such factors have been proposed: the apoptosis-inducing factor (AIF) [22] and cytochrome c [23] . These factors appear to differ in the way that they effect the end stages of apoptosis (see Figure 2 ), but the release of both AIF and cytochrome c from the intermembrane space appears to be under the control of Bcl-2 [22, 23] . On release from the mitochondrion, cytochrome c, which normally functions as a mobile transporter of electrons between complexes III and IV (see Figure 1) , participates in the activation of caspases implicated in apoptosis [23] . In a cell-free system purified cytochrome c, together with dATP, triggers the activation of Apaf-1 (apoptosis-activating factor-1). This then cleaves and activates caspase-9, which in turn activates caspase-3 (CPP32) [24] . These caspases are responsible for the key proteolytic events characterizing apoptosis. AIF appears to act further downstream, is itself capable of causing nuclear chromatin condensation, and is insensitive to inhibitors of caspase-3 [22] .
Considerable uncertainty surrounds the mechanism for the release of AIF and cytochrome c from the intermembrane space into the cytosol (see Figure 2) . While the release of both is under the control of the Bcl-2 protein(s), the release of AIF has been strongly correlated with the opening of the mitochondrial permeability transition pore, depolarization of the mitochondrial membrane, an increase in mitochondrial volume and rupture of the mitochondrial outer membrane [22] . Kroemer and colleagues [22] propose that AIF can then leave the intermembrane space in a non-specific fashion. In contrast, the release of cytochrome c has been reported to occur prior to a decrease in mitochondrial membrane potential, and to be unaffected by inhibitors of pore opening [25] .
Perspectives
The mitochondrion occupies the centre stage in current theories of both acute and chronic neurodegeneration. With respect to the former, the development of drugs to control the uptake of Ca 2ϩ by mitochondria during post-ischaemic Porin/Bcl-X L Protein kinases DNA repair proteins RNA splicing proteins reperfusion, or to limit the damage to mitochondrial bioenergetics resulting from such accumulation, may provide an alternative to current therapies. With respect to chronic neurodegenerative disease, the advent of cybrid technology allows functional investigations of human mitochondrial mutations to be carried out, and this may allow the development of patient-specific therapy regimes. For instance, if a metabolic defect is found, then perhaps agents that can improve oxidative phosphorylation downstream of this defect may be useful. In addition, identifying mtDNA mutations will open up the possibility of gene therapy for neurodegenerative disorders. Certainly, at the present time, if mutations in either mtDNA or nuclear DNA which predispose individuals to degenerative diseases can be found, they will enable the development of presymptomatic disease testing and genetic counselling. Interfering with an apoptotic cascade may only serve to rescue irreparably damaged neurons, and thus be of little value in the therapy of neurodegenerative disorders. However, if upstream mitochondrial dysfunction is responsible for the cell damage that initiates subsequent apoptosis to remove the defective cell, then it is apparent that an ability to prevent this dysfunction might prevent the subsequent cell destruction. Conversely, facilitation of mitochondrially induced apotosis in cancer may contribute to elucidating the close interrelationship between defective cell-cycle control and failed apoptosis in these conditions.
Summary
• A prolonged decrease in ATP levels underlies a number of neurodegenerative disorders.
• Defects in oxidative phosphorylation are associated with a number of neurodegenerative disorders.
• Mitochondria also play an important role in mediating the initiation of apoptosis.
